We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 648

India: Delhi High Court grants injunction in favor of GSK
  • SS Rana & Co
  • India
  • December 20 2016

In this case, Glaxosmithkline Pharmaceuticals (hereinafter referred to as the 'Plaintiff') filed a suit against Sarath Kumar Reddy (hereinafter

Delhi High Court strikes down notification dated 10 March 2016 issued by the government of India banning 344 fixed dose combination (FDC) drugs
  • Khaitan & Co
  • India
  • December 5 2016

A single judge of the Delhi High Court, Justice Rajiv Sahai Endlaw vide his Order and Judgment dated 1 December 2016 has struck down the notification

The real meaning of 'efficacy'
  • LexOrbis
  • India
  • November 30 2016

In 2005 India amended the Patents Act to introduce protection for product inventions, including patents for pharmaceuticals. Section 3(d) of the

Indian Market Regulatory Update
  • Squire Patton Boggs
  • India
  • November 14 2016

The International Monetary Fund (IMF) pegs India's growth at 7.6 in the year ended March 31, 2016 and estimates a growth of 7.4 for 2016 and 2017

Pharmaceutical trademark case law analysis
  • WS Kane & Co
  • India
  • September 12 2016

In the 21st century, trademarks have gained paramount importance in every industry. Pharmaceutical trademarks are particularly important, since they

Controller overreach or common sense? - a tale of section 83 of the Patents Act
  • Lakshmikumaran & Sridharan
  • India
  • August 23 2016

In IPR Amicus Issue No. 49, dated August 2015, the interplay between the Biological Diversity Act, 2002 (BDA), and intellectual property rights in

Sun enforces its rights in VENIZ
  • RNA IP Attorneys
  • India
  • August 3 2016

The Plaintiff, Sun Pharmaceuticals Industries Ltd, (Sun) filed the suit for trademark infringement, passing off and damages against Cadila Healthcare

Linking Patent and Data Exclusivity
  • RNA IP Attorneys
  • India
  • August 3 2016

It is rightly said that developing a drug is a risky business as launching a new drug to market requires huge amount of investment in terms of money

Indian Government announces easing of foreign direct investment rules
  • Penningtons Manches LLP
  • India
  • July 27 2016

The Indian Department of Industrial Policy & Promotion (DIPP) has announced sweeping changes to its foreign direct investment policy with the release

India: A strict approach for a growing industry
  • RNA IP Attorneys
  • India, USA
  • July 1 2016

The Indian pharmaceutical market grew at a rate of 17.46 in 2015 and is expected to expand by over 15 by 2020, when it is estimated that it will be